Open Label, Randomized, Multicenter Phase II Study of a Combination of Torisel (Temsirolimus) and Avastin (Bevacizumab) Versus Sutent (Sunitinib) and Versus a Combination of Avastin (Bevacizumab) and Roferon (Interferon [IFN] Alpha-2a) in First-Line Treatment of Patients With Metastatic Renal Cell Carcinoma.

Trial Profile

Open Label, Randomized, Multicenter Phase II Study of a Combination of Torisel (Temsirolimus) and Avastin (Bevacizumab) Versus Sutent (Sunitinib) and Versus a Combination of Avastin (Bevacizumab) and Roferon (Interferon [IFN] Alpha-2a) in First-Line Treatment of Patients With Metastatic Renal Cell Carcinoma.

Completed
Phase of Trial: Phase II

Latest Information Update: 05 Jul 2016

At a glance

  • Drugs Bevacizumab (Primary) ; Temsirolimus (Primary) ; Interferon alpha-2a; Sunitinib
  • Indications Renal cell carcinoma
  • Focus Therapeutic Use
  • Acronyms TORAVA
  • Most Recent Events

    • 15 Sep 2015 Results (metabolomic fingerprint analysis) published in the British Journal of Cancer.
    • 05 Jun 2012 Updated long-term survival results presented at the 48th Annual Meeting of the American Society of Clinical Oncology.
    • 09 Jun 2011 Results published in the Lancet Oncology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top